Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
121,543,157
-
Number of holders
-
55
-
Total 13F shares, excl. options
-
48,682,678
-
Shares change
-
-140,219
-
Total reported value, excl. options
-
$106,127,667
-
Value change
-
-$321,362
-
Number of buys
-
18
-
Number of sells
-
-20
-
Price
-
$2.18
Significant Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) as of Q3 2023
61 filings reported holding TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q3 2023.
Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) has 55 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48,682,678 shares
of 121,543,157 outstanding shares and own 40% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (11,370,376 shares), Frazier Life Sciences Management, L.P. (6,881,090 shares), Rubric Capital Management LP (5,684,420 shares), Fairmount Funds Management LLC (5,163,287 shares), VIKING GLOBAL INVESTORS LP (4,400,000 shares), VR Adviser, LLC (3,422,397 shares), BlackRock Inc. (2,148,263 shares), VANGUARD GROUP INC (1,957,875 shares), Opaleye Management Inc. (1,705,900 shares), and MAI Capital Management (1,451,400 shares).
This table shows the top 55 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.